Valence Life Sciences

Valence targets life sciences companies that use computation and artificial intelligence as core components of their therapeutic or diagnostic platforms. The firm invests across venture and growth stages, focusing on drug discovery platforms, digital health infrastructure, and precision medicine rather than traditional asset-centric biotech plays.

Traditional biotech VCs typically invest in specific drug candidates and manage binary clinical-trial risk. Valence focuses on platform companies — businesses building enabling technologies like AI-driven drug discovery, computational biology tools, and digital health infrastructure — which have broader technical moats and potentially faster capital cycles than single-asset biotech bets.

While Valence is headquartered in New York, the life sciences sector is inherently global. The firm's investment scope likely includes North America and select European opportunities, particularly in AI-driven discovery where talent and innovation clusters exist in both the US and Europe.

Valence does not publicly list its principals or investment committee members on its website or LinkedIn. The firm appears to operate with a concentrated, specialized partnership group, a common structure for deeply technical venture and growth equity firms where domain expertise drives sourcing and diligence.

Valence has not publicly disclosed its assets under management or fund size. The firm maintains a low profile consistent with many specialist private equity managers that raise capital on a deal-by-deal or limited-partner basis without broad institutional reporting.